Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown. COVID-19 patients with hypertension were enrolled to evaluate the effect of RAS inhibitors.

肾素-血管紧张素系统（renin-angiotensin system, RAS）功能紊乱已在冠状病毒感染疾病（coronavirus infection disease, COVID-19）患者中被发现，但RAS抑制剂，如血管紧张素转换酶抑制剂（angiotensin-converting enzyme inhibitors, ACEIs）与血管紧张素Ⅱ1型受体阻滞剂（angiotensin II type 1 receptor blockers, ARBs），是否与临床结局相关仍不明确。该数据集纳入合并高血压的COVID-19患者，以评估RAS抑制剂的临床效应。